institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published Waltham, United StatesUpdated

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

Summary by Financial Post
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass. -- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; “Modalis”), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular …

Bias Distribution

  • 100% of the sources lean Right
100% Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Financial Post broke the news in Canada on Sunday, June 8, 2025.
Sources are mostly out of Canada (1)

You have read 4 out of your 5 free daily articles.

Our use of cookies
Unlike other news sites, we do not share or sell your data to third-parties for targeted ads.
By continuing to use our application or website, you agree to our Terms of Service and Privacy Policy.